{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:10:44Z","timestamp":1780078244981,"version":"3.54.0"},"reference-count":39,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Tacrolimus is currently the most commonly used immunosuppressive agent after liver transplantation, administered to prevent allograft rejection, but it is also associated with numerous adverse effects. Purpose: The aim of this review was to summarize the most clinically relevant and well-documented adverse effects of tacrolimus after liver transplantation, focusing on their mechanisms, clinical presentation, approximate incidence, and overall clinical significance. Methods: We searched the PubMed and Medline databases and included articles, randomized controlled trials, cohort studies, review articles, and case reports published between 2016 and 2026. Results: The most common causes of morbidity in the early days following liver transplantation and initiation of tacrolimus therapy are acute nephrotoxicity, systemic infections, and signs of neurotoxicity. In the majority of patients, these manifestations resolved after dose reduction or complete discontinuation of the drug. During the early post-transplant period, opportunistic infections were the main cause of morbidity, with bacteria being the most frequent pathogens, while mortality in certain fungal infections reached up to 50%. While acute toxicities are primarily influenced by drug dose, long-term use of tacrolimus, regardless of dose, can lead to the development of malignancies, metabolic disorders, cardiovascular diseases, and chronic kidney disease, with incidence estimates varying widely. Conclusions: Consistent monitoring of patients on tacrolimus is crucial to ensure maximum therapeutic benefit and to reduce the risk of associated adverse effects.<\/jats:p>","DOI":"10.3390\/jcm15114176","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:36:18Z","timestamp":1780076178000},"page":"4176","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tacrolimus-Associated Adverse Effects After Liver Transplantation: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"given":"Nikola","family":"Bakovic","sequence":"first","affiliation":[{"name":"Clinic for Gastroenterology and Hepatology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1137-1141","authenticated-orcid":false,"given":"Ivana","family":"Pantic","sequence":"additional","affiliation":[{"name":"Clinic for Gastroenterology and Hepatology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Vasiljevic","sequence":"additional","affiliation":[{"name":"Clinic for Gastroenterology and Hepatology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Vojnovic","sequence":"additional","affiliation":[{"name":"Clinic for Gastroenterology and Hepatology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Micic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Clinic of Emergency Surgery, Emergency Center, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6608-5233","authenticated-orcid":false,"given":"Tamara","family":"Milovanovic","sequence":"additional","affiliation":[{"name":"Clinic for Gastroenterology and Hepatology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","unstructured":"Dababneh, Y., and Mousa, O.Y. (2025, December 15). Liver transplantation, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559161\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101363","DOI":"10.1016\/j.jceh.2024.101363","article-title":"Rejection in liver transplantation recipients","volume":"14","author":"Maddur","year":"2024","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): Molecular and cellular mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J. Antibiot."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5125\/jkaoms.2023.49.6.311","article-title":"Review of two immunosuppressants: Tacrolimus and cyclosporine","volume":"49","author":"Lee","year":"2023","journal-title":"J. Korean Assoc. Oral Maxillofac. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1097\/TP.0000000000002700","article-title":"Improved survival in liver transplant patients receiving prolonged-release tacrolimus-based immunosuppression in the European Liver Transplant Registry (ELTR): An extension study","volume":"103","author":"Adam","year":"2019","journal-title":"Transplantation"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Haddad, E.M., McAlister, V.C., Renouf, E., Malthaner, R.A., Kjaer, M.S., and Gluud, L.L. (2006). Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst. Rev., CD005161.","DOI":"10.1002\/14651858.CD005161"},{"key":"ref_8","unstructured":"Araya, A.A., and Tasnif, Y. (2025, December 20). Tacrolimus, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544318\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00125480-199707000-00032","article-title":"Tacrolimus (FK506)-associated renal pathology","volume":"4","author":"Randhawa","year":"1997","journal-title":"Adv. Anat. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1097\/TP.0000000000002760","article-title":"Area under trough concentrations of tacrolimus as a predictor of progressive renal impairment after liver transplantation","volume":"103","author":"Guerrero","year":"2019","journal-title":"Transplantation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/lt.26298","article-title":"Early everolimus-facilitated reduced tacrolimus in liver transplantation: Results from the randomized HEPHAISTOS trial","volume":"28","author":"Nashan","year":"2022","journal-title":"Liver Transpl."},{"key":"ref_12","first-page":"9312481","article-title":"Tacrolimus-induced type IV renal tubular acidosis following liver transplantation","volume":"2017","author":"Schmoyer","year":"2017","journal-title":"Case Rep. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/lt.24514","article-title":"Favorable long-term outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: Results of a single-center cohort","volume":"22","author":"Gastaca","year":"2016","journal-title":"Liver Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.29271\/jcpsp.2019.11.1048","article-title":"Clinical efficacy and safety of tacrolimus in Pakistani living donor liver transplant recipients","volume":"29","author":"Azam","year":"2019","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/jlts.2001.27475","article-title":"Neurotoxicity of immunosuppressive drugs","volume":"7","author":"Wijdicks","year":"2001","journal-title":"Liver Transpl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1111\/ajt.14317","article-title":"Prevention of the osmotic demyelination syndrome after liver transplantation: A multidisciplinary perspective","volume":"17","author":"Crismale","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Jin, B., Kim, G.Y., and Cheon, S.M. (2021). Tacrolimus-induced neurotoxicity from bipolar disorder to status epilepticus under the therapeutic serum level: A case report. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02479-z"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1007\/s10072-025-08248-x","article-title":"Rapidly progressive dementia in tacrolimus neurotoxicity: Rare but reversible","volume":"46","author":"Chand","year":"2025","journal-title":"Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.transproceed.2020.01.076","article-title":"Tacrolimus-associated psychotic disorder: A report of 2 cases","volume":"52","year":"2020","journal-title":"Transpl. Proc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4254\/wjh.v16.i9.1297","article-title":"Calcineurin inhibitors-related posterior reversible encephalopathy syndrome in liver transplant recipients: Three case reports and review of literature","volume":"16","author":"Gong","year":"2024","journal-title":"World J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gmitterov\u00e1, K., Min\u00e1r, M., \u017digrai, M., Ko\u0161utzk\u00e1, Z., Ku\u0161n\u00edrov\u00e1, A., and Valkovi\u010d, P. (2018). Tacrolimus-induced parkinsonism in a patient after liver transplantation: Case report. BMC Neurol., 18.","DOI":"10.1186\/s12883-018-1052-1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.1177\/0300060519883750","article-title":"Acute symptomatic seizure due to tacrolimus-related encephalopathy after liver transplantation: Two case reports","volume":"47","author":"Li","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/clinpract12030033","article-title":"A case of tacrolimus maculopathy","volume":"12","author":"Santarelli","year":"2022","journal-title":"Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1600-6143.2006.01360.x","article-title":"Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: A meta-analysis","volume":"6","author":"McAlister","year":"2006","journal-title":"Am. J. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.3748\/wjg.v22.i6.2133","article-title":"Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation","volume":"22","author":"Song","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijsu.2017.12.037","article-title":"Higher tacrolimus blood concentration is related to increased risk of post-transplantation diabetes mellitus after living donor liver transplantation","volume":"51","author":"Song","year":"2018","journal-title":"Int. J. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Becker, J.C., Houben, R., Vetter, C.S., and Br\u00f6cker, E.B. (2006). The carcinogenic potential of tacrolimus ointment beyond immune suppression: A hypothesis creating case report. BMC Cancer, 6.","DOI":"10.1186\/1471-2407-6-7"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.17021","article-title":"Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation","volume":"22","author":"Colmenero","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jceh.2014.07.004","article-title":"Infections after orthotopic liver transplantation","volume":"4","author":"Pedersen","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0213-005X(12)70081-2","article-title":"Multidrug-resistant bacterial infection in solid organ transplant recipients","volume":"30","author":"Cervera","year":"2012","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e14049","DOI":"10.1111\/tid.14049","article-title":"Invasive aspergillosis in liver transplant recipients","volume":"25","author":"Melenotte","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.12998\/wjcc.v7.i18.2746","article-title":"Sinusoidal obstruction syndrome: A systematic review of etiologies, clinical symptoms, and magnetic resonance imaging features","volume":"7","author":"Zhang","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00595-023-02770-1","article-title":"Early-onset hepatic veno-occlusive disease after liver transplantation: An institutional experience and analysis of a literature-based cohort","volume":"54","author":"Endo","year":"2024","journal-title":"Surg. Today"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.12998\/wjcc.v10.i36.13408","article-title":"Hepatic sinusoidal obstruction syndrome induced by tacrolimus following liver transplantation: Three case reports","volume":"10","author":"Jiang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/j.cgh.2020.08.049","article-title":"Hepatic sinusoidal obstruction syndrome post-liver transplantation: A rare complication of tacrolimus","volume":"20","author":"Li","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/gastro\/goaa056","article-title":"Hepatic sinusoidal obstruction syndrome due to tacrolimus in a liver-transplantation recipient","volume":"9","author":"Zhou","year":"2020","journal-title":"Gastroenterol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e11076","DOI":"10.1097\/MD.0000000000011076","article-title":"Management of hepatic vein occlusive disease after liver transplantation: A case report with literature review","volume":"97","author":"Hou","year":"2018","journal-title":"Medicine"},{"key":"ref_38","unstructured":"European Association for the Study of the Liver (EASL) (2024). EASL Clinical Practice Guidelines: Liver transplantation. J. Hepatol., 81, 412\u2013474."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.cca.2011.10.013","article-title":"Pharmacogenetic biomarkers: Cytochrome P450 3A5","volume":"413","author":"MacPhee","year":"2012","journal-title":"Clin. Chim. Acta"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4176\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:52:43Z","timestamp":1780077163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114176"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114176","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}